Sector
PharmaceuticalsOpen
₹5,663Prev. Close
₹5,664Turnover(Lac.)
₹3,196.17Day's High
₹5,825Day's Low
₹5,54052 Week's High
₹6,451.1552 Week's Low
₹3,701Book Value
₹953.74Face Value
₹10Mkt Cap (₹ Cr.)
25,547.82P/E
40.01EPS
139.83Divi. Yield
2.959 Aug 2024
12:00 AM
AGM
Announcement Date: 09 Aug, 2024
13 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
Ativan is a common medication used predominantly for anxiety disorders, whereas Pacitane is used for Parkinson’s disease and other neurological conditions.
The agreement, which is discussed up to April and approved by Pfizer's Board of Directors, will be for five years, with discussions ending on 21 February 2025.
Revenue from operations decline marginally by 0.4% YoY at ₹538 crore, as against ₹540 crore in Q3 FY24
At the operating level, EBITDA increased by 60.2%, reaching ₹177.5 Crore in the first quarter of this fiscal year, compared to ₹110.8 Crore in the same quarter last year.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 45.75 | 45.75 | 45.75 | 45.75 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 3,549.79 | 3,161.55 | 2,818.66 | 2,347.29 |
Net Worth | 3,595.54 | 3,207.3 | 2,864.41 | 2,393.04 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 2,610.99 | 2,238.55 | 2,151.65 | 1,968.51 |
yoy growth (%) | 16.63 | 4.03 | 9.3 | 0.11 |
Raw materials | -948.03 | -797.74 | -792.4 | -739.68 |
As % of sales | 36.3 | 35.63 | 36.82 | 37.57 |
Employee costs | -403.67 | -361.06 | -364.51 | -314.29 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 772.89 | 668.72 | 642.49 | 547.91 |
Depreciation | -115 | -109.41 | -103.24 | -66.25 |
Tax paid | -160.33 | -171.11 | -133.36 | -187.84 |
Working capital | 385.47 | -980.02 | 712.61 | 190.64 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 16.63 | 4.03 | 9.3 | 0.11 |
Op profit growth | 17.35 | 24.37 | 14.44 | 43.29 |
EBIT growth | 14.55 | 4.66 | 19.15 | 41.55 |
Net profit growth | 23.1 | -2.26 | 41.39 | 6.91 |
| Particulars (Rupees in Crores.) | Nov-2009 | Nov-2008 | Nov-2007 | Nov-2006 | Nov-2005 |
|---|---|---|---|---|---|
Gross Sales | 772.27 | 681.7 | 676.69 | 770.59 | 702.34 |
Excise Duty | 0 | 0 | 0 | 60.4 | 54.15 |
Net Sales | 772.27 | 681.7 | 676.69 | 710.2 | 648.17 |
Other Operating Income | 24.37 | 22.89 | 0 | 0 | 0 |
Other Income | 71.05 | 278.01 | 343.07 | 59.59 | 41.06 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.6 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,484 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.1 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,164 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Company Sec. & Compli. Officer
Prajeet Nair
Independent Director
MEENA GANESH
Managing Director
Meenakshi Nevatia
Director (Finance) & CFO
Amit Agarwal
Independent Director
L Krishnakumar
Independent Director
Sonia Singh
Executive Director
P. Rengan
Chairman & Non Executive Dir.
Pradip P Shah
The Capital 1802/1901 Plot-C70,
G Bl Bandra Kurla Cpx Bandra-E,
Maharashtra - 400051
Tel: 91-22-66932000
Website: http://www.pfizerindia.com
Email: contactus.india@pfizer.com
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@kfintech.com
Summary
Pfizer Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company offer a portfolio of 150 specialised medicines in 15 therapeutic areas across 4 busine...
Read More
Reports by Pfizer Ltd
What is the Pfizer Ltd share price today?
What is the Market Cap of Pfizer Ltd?
What is the PE and PB ratio of Pfizer Ltd?
What is the 52 Week High and Low of Pfizer Ltd?
What is the CAGR of Pfizer Ltd?
What is the shareholding pattern of Pfizer Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
